Clinical Trial Update: Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX) [Phase 2, Phase 3]

View source ↗

Summary

Clinical study of cannabidiol in children and adolescents with Fragile X Syndrome has completed Phase 2/3 with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Drugs mentioned

• Cannabidiol (cannabidiol)

Snippet

Sponsor: Zynerba Pharmaceuticals, Inc. | Conditions: Fragile X Syndrome | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2022-06-16